TGA-Registered Sublingual Immunotherapy Product
Actair is a TGA-registered sublingual immunotherapy (SLIT) product developed in Europe for the treatment of dust mite allergy, specifically targeting Dermatophagoides pteronyssinus and Dermatophagoides farinae. It offers a needle-free, home-based option after an initial supervised dose, suitable for patients seeking convenient management of dust mite allergy.
Overview
Actair provides targeted treatment for patients with confirmed dust mite sensitisation, reducing the risk of allergy symptoms while supporting quality-of-life improvements through daily home administration.
Its TGA registration assures compliance with Australian safety and quality standards.
Safety Profile
Actair has a well-documented safety profile. Most adverse events are local and mild, including:
Common side effects include:
Oral or throat itching or discomfort
Mild swelling under the tongue
Temporary irritation or tingling sensations
Effectiveness
Clinical trials show that Actair can significantly reduce dust mite allergy symptoms and decrease medication use over a 3–5 year treatment course.
Regular daily dosing is critical for achieving optimal outcomes, and patients may begin to notice improvement after several months.
3–5 year treatment course
Treatment options
Single allergen therapy
Single allergen therapy:
Focused on dust mites; Actair specifically addresses D. pteronyssinus and D. farinae.
Multi-allergen therapy
Multi-allergen therapy:
Not applicable; Actair targets dust mites exclusively.
Both TGA-registered and non-registered options exist.
Clinics must inform patients that all options are privately funded in Australia, with total treatment costs varying from several hundred to several thousand dollars per year.
First dose administered under clinic supervision
Subsequent daily doses taken at home under the tongue
Consistent daily dosing is critical for effectiveness
Contact the clinic if any severe reactions occur
Patient Suitability
Actiar may be appropriate for patients who:
Have confirmed IgE-mediated temperate dust mite allergy
Are looking for a needle-free home-based option
Can commit to daily adherence over the treatment period
Desire a TGA-registered SLIT product for dust mite management
Australian Context
Not PBS-subsidised; treatment is privately funded
Part of a personalised allergen immunotherapy plan supervised by a clinician
Conclusion
Actair provides a safe, effective, and convenient SLIT option for patients with dust mite allergy.
Its targeted action on D. pteronyssinus and D. farinae, combined with home-based daily dosing, makes it an accessible and patient-friendly choice.
Specialist supervision ensures optimal safety and treatment outcomes.
